Full Text:   <874>

Summary:  <309>

Suppl. Mater.: 

CLC number: 

On-line Access: 2024-08-27

Received: 2023-10-17

Revision Accepted: 2024-05-08

Crosschecked: 2024-06-24

Cited: 0

Clicked: 1100

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Duo LV

https://orcid.org/0000-0003-0957-2630

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2024 Vol.25 No.6 P.529-540

http://doi.org/10.1631/jzus.B2300538


Clinical characteristics and outcomes of hospitalized kidney transplant recipients with COVID-19 infection in China during the Omicron wave: a single-center cohort study


Author(s):  Duo LV, Xishao XIE, Qinyun YANG, Zhimin CHEN, Guangjun LIU, Wenhan PENG, Rending WANG, Hongfeng HUANG, Jianghua CHEN, Jianyong WU

Affiliation(s):  Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; more

Corresponding email(s):   wujianyong1964@zju.edu.cn

Key Words:  Coronavirus disease 2019 (COVID-19), Kidney transplant, Hospitalization, Mortality


Share this article to: More <<< Previous Article|

Duo LV, Xishao XIE, Qinyun YANG, Zhimin CHEN, Guangjun LIU, Wenhan PENG, Rending WANG, Hongfeng HUANG, Jianghua CHEN, Jianyong WU. Clinical characteristics and outcomes of hospitalized kidney transplant recipients with COVID-19 infection in China during the Omicron wave: a single-center cohort study[J]. Journal of Zhejiang University Science B, 2024, 25(6): 529-540.

@article{title="Clinical characteristics and outcomes of hospitalized kidney transplant recipients with COVID-19 infection in China during the Omicron wave: a single-center cohort study",
author="Duo LV, Xishao XIE, Qinyun YANG, Zhimin CHEN, Guangjun LIU, Wenhan PENG, Rending WANG, Hongfeng HUANG, Jianghua CHEN, Jianyong WU",
journal="Journal of Zhejiang University Science B",
volume="25",
number="6",
pages="529-540",
year="2024",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2300538"
}

%0 Journal Article
%T Clinical characteristics and outcomes of hospitalized kidney transplant recipients with COVID-19 infection in China during the Omicron wave: a single-center cohort study
%A Duo LV
%A Xishao XIE
%A Qinyun YANG
%A Zhimin CHEN
%A Guangjun LIU
%A Wenhan PENG
%A Rending WANG
%A Hongfeng HUANG
%A Jianghua CHEN
%A Jianyong WU
%J Journal of Zhejiang University SCIENCE B
%V 25
%N 6
%P 529-540
%@ 1673-1581
%D 2024
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2300538

TY - JOUR
T1 - Clinical characteristics and outcomes of hospitalized kidney transplant recipients with COVID-19 infection in China during the Omicron wave: a single-center cohort study
A1 - Duo LV
A1 - Xishao XIE
A1 - Qinyun YANG
A1 - Zhimin CHEN
A1 - Guangjun LIU
A1 - Wenhan PENG
A1 - Rending WANG
A1 - Hongfeng HUANG
A1 - Jianghua CHEN
A1 - Jianyong WU
J0 - Journal of Zhejiang University Science B
VL - 25
IS - 6
SP - 529
EP - 540
%@ 1673-1581
Y1 - 2024
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2300538


Abstract: 
BackgroundFollowing the short-term outbreak of coronavirus disease 2019 (COVID-19) in December 2022 in China, clinical data on kidney transplant recipients (KTRs) with COVID-19 are lacking.
MethodsWe conducted a single-center retrospective study to describe the clinical features, complications, and mortality rates of hospitalized KTRs infected with COVID-19 between Dec. 16, 2022 and Jan. 31, 2023. The patients were followed up until Mar. 31, 2023.
ResultsA total of 324 KTRs with COVID-19 were included. The median age was 49 years. The median time between the onset of symptoms and admission was 13 d. Molnupiravir, azvudine, and nirmatrelvir/ritonavir were administered to 67 (20.7%), 11 (3.4%), and 148 (45.7%) patients, respectively. Twenty-nine (9.0%) patients were treated with more than one antiviral agent. Forty-eight (14.8%) patients were treated with tocilizumab and 53 (16.4%) patients received baricitinib therapy. The acute kidney injury (AKI) occurred in 81 (25.0%) patients and 39 (12.0%) patients were admitted to intensive care units. Fungal infections were observed in 55 (17.0%) patients. Fifty (15.4%) patients lost their graft. The 28-d mortality rate of patients was 9.0% and 42 (13.0%) patients died by the end of follow-up. Multivariate Cox regression analysis identified that cerebrovascular disease, AKI incidence, interleukin (IL)‍-6 level of >6.8 pg/mL, daily dose of corticosteroids of >50 mg, and fungal infection were all associated with an increased risk of death for hospitalized patients.
ConclusionsOur findings demonstrate that hospitalized KTRs with COVID-19 are at high risk of mortality. The administration of immunomodulators or the late application of antiviral drugs does not improve patient survival, while higher doses of corticosteroids may increase the death risk.

在2019冠状病毒病暴发流行期间感染并住院治疗的肾移植受者的临床特征与预后:一项中国单中心队列研究

吕朵1,2,谢锡绍3,4,5,6,7,杨钦云8,陈芷珉3,4,5,6,7,刘光军3,4,5,6,7,彭文翰3,4,5,6,7,王仁定3,4,5,6,7,黄洪锋3,4,5,6,7,陈江华3,4,5,6,7,吴建永3,4,5,6,7
1浙江大学医学院附属第一医院临床药学部,中国杭州市,310003
2浙江省药物临床研究与评价技术重点实验室,中国杭州市,310003
3浙江大学医学院附属第一医院肾脏病中心,中国杭州市,310003
4浙江省肾脏病防治技术研究重点实验室,中国杭州市,310003
5浙江大学肾脏病研究所,中国杭州市,310003
6浙江省肾脏与泌尿系统疾病临床创医学研究中心,中国杭州市,310003
7中国中医药管理局III级实验室,中国杭州市,310003
8浙江大学医学院附属第一医院信息中心,中国杭州市,310003
摘要:2022年12月2019冠状病毒病(COVID-19)在中国出现短期的暴发流行,大量肾移植受者在感染COVID-19后需住院治疗。本研究回顾分析了在2022年12月16日至2023年1月31日期间感染COVID-19并在浙江大学医学院附属第一医院住院治疗的肾移植受者的临床特征和预后,随访截至2023年3月31日。本研究共纳入324名患者,其中位年龄为49岁,从出现症状到入院的中位时间为13天。分别有67例(20.7%)、11例(3.4%)和148例(45.7%)患者接受了莫那匹韦、阿兹夫定和奈玛特韦/利托那韦治疗,29例(9.0%)患者接受了多种抗病毒药物治疗,48例(14.8%)接受了托珠单抗治疗,53例(16.4%)接受了巴瑞替尼治疗。其中,81例(25.0%)发生急性肾损伤(AKI),39例(12.0%)转入ICU治疗,55例(17.0%)发生真菌感染,50例(15.4%)最终发生移植肾失功。患者的28天死亡率为9.0%,截至随访终点时共有42例(13.0%)患者死亡。多因素Cox回归分析显示合并脑血管疾病、AKI出现、白介素-6(IL-6)水平大于6.8 pg/mL、每日平均糖皮质激素剂量大于50 mg以及真菌感染等因素与住院患者死亡风险增加相关。结果表明,感染COVID-19后需住院治疗的肾移植受者死亡率很高。此外,服用免疫调节剂或过迟应用抗病毒药物,并不能提高患者生存率,而且大剂量的糖皮质激素使用则会增加死亡风险。

关键词:2019冠状病毒病(COVID-19);肾移植;住院治疗;死亡率

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]AhmadFB, CisewskiJA, XuJQ, et al., 2023. COVID-19 mortality update – United States, 2022. MMWR Morb Mortal Wkly Rep, 72(18):493-496.

[2]AveryRK, 2022. Update on COVID-19 therapeutics for solid organ transplant recipients, including the omicron surge. Transplantation, 106(8):1528-1537.

[3]AzziY, BartashR, ScaleaJ, et al., 2021. COVID-19 and solid organ transplantation: a review article. Transplantation, 105(1):37-55.

[4]BergerB, HazzanM, KamarN, et al., 2022. Absence of mortality differences between the first and second COVID-19 waves in kidney transplant recipients. Kidney Int Rep, 7(12):2617-2629.

[5]BernalE, GimenoL, AlcarazMJ, et al., 2021. Activating killer-cell immunoglobulin-like receptors are associated with the severity of coronavirus disease 2019. J Infect Dis, 224(2):229-240.

[6]CaillardS, AnglicheauD, MatignonM, et al., 2020. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney Int, 98(6):1549-1558.

[7]ChanL, ChaudharyK, SahaA, et al., 2021. AKI in hospitalized patients with COVID-19. J Am Soc Nephrol, 32(1):151-160.

[8]ChaudhuriD, SasakiK, KarkarA, et al., 2021. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med, 47(5):521-537.

[9]COVID-19 Excess Mortality Collaborators, 2022. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet, 399(10334):1513-1536.

[10]DanielE, SekulicM, KudoseS, et al., 2021. Kidney allograft biopsy findings after COVID-19. Am J Transplant, 21(12):4032-4042.

[11]DaoudA, AlqassiehA, AlkhaderD, et al., 2021. Immunosuppression in kidney transplant recipients with COVID-19 infection – where do we stand and where are we heading? Ren Fail, 43(1):273-280.

[12]FangXY, LiS, YuH, et al., 2020. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging, 12(13):‍‍‍12493-12503.

[13]FarkashEA, WilsonAM, JentzenJM, 2020. Ultrastructural evidence for direct renal infection with SARS-CoV-2. J Am Soc Nephrol, 31(8):1683-1687.

[14]FavàA, CucchiariD, MonteroN, et al., 2020. Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: a multicentric cohort study. Am J Transplant, 20(11):3030-3041.

[15]GangneuxJP, DannaouiE, FekkarA, et al., 2022. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med, 10(2):180-190.

[16]GérardAO, BarbosaS, AnglicheauD, et al., 2022. Association between maintenance immunosuppressive regimens and COVID-19 mortality in kidney transplant recipients. Transplantation, 106(10):2063-2067.

[17]GuptaS, WangW, HayekSS, et al., 2021. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med, 181(1):41-51.

[18]HajibarataliB, AminiH, DaliliN, et al., 2023. Clinical outcomes of kidney recipients with COVID-19 (COVID-19 in kidney recipients). Transpl Immunol, 76:101772.

[19]HartzellS, BinS, BenedettiC, et al., 2020. Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients. Am J Transplant, 20(11):3149-3161.

[20]JimenoS, VenturaPS, CastellanoJM, et al., 2021. Prognostic implications of neutrophil-lymphocyte ratio in COVID-19. Eur J Clin Invest, 51(1):e13404.

[21]KlopfensteinT, GendrinV, Kadiane-OussouNJ, et al., 2022. Tocilizumab in COVID-19 pneumonia: practical proposals based on a narrative review of randomised trials. Rev Med Virol, 32(1):e2239.

[22]KremerD, PietersTT, VerhaarMC, et al., 2021. A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: lessons to be learned. Am J Transplant, 21(12):3936-3945.

[23]KronbichlerA, GaucklerP, WindpesslM, et al., 2020. COVID-19: implications for immunosuppression in kidney disease and transplantation. Nat Rev Nephrol, 16(7):365-367.

[24]MahalingasivamV, SuGB, IwagamiM, et al., 2022. COVID-19 and kidney disease: insights from epidemiology to inform clinical practice. Nat Rev Nephrol, 18(8):485-498.

[25]MallhiTH, KhanYH, AlzareaAI, et al., 2022. Incidence, risk factors and outcomes of acute kidney injury among COVID-19 patients: a systematic review of systematic reviews. Front Med (Lausanne), 9:973030.

[26]MassetC, Gautier-VargasG, CantarovichD, et al., 2022. Occurrence of de novo donor-specific antibodies after COVID-19 in kidney transplant recipients is low despite immunosuppression modulation. Kidney Int Rep, 7(5):983-992.

[27]MendozaMA, RanganathN, ChesdachaiS, et al., 2023. Immunomodulators for severe coronavirus disease-2019 in transplant patients: do they increase the risk of secondary infection? Transpl Infect Dis, 25(2):e14050.

[28]NabL, ParkerEPK, AndrewsCD, et al., 2023. Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform. Lancet Public Health, 8(5):e364-e377.

[29]NadimMK, ForniLG, MehtaRL, et al., 2020. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol, 16(12):747-764.

[30]National Institutes of Health (US), 2021. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. National Institutes of Health (US), Bethesda, USA. https://pubmed.ncbi.nlm.nih.gov/34003615

[31]NgJH, HirschJS, HazzanA, et al., 2021. Outcomes among patients hospitalized with COVID-19 and acute kidney injury. Am J Kidney Dis, 77(2):204-215.e1.

[32]NimmoA, GardinerD, Ushiro-LumbI, et al., 2022. The global impact of COVID-19 on solid organ transplantation: two years into a pandemic. Transplantation, 106(7):1312-1329.

[33]PereiraMR, AversaMM, FarrMA, et al., 2020. Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study. Am J Transplant, 20(11):‍‍3198-3205.

[34]Pérez-SáezMJ, BlascoM, Redondo-PachónD, et al., 2020. Use of tocilizumab in kidney transplant recipients with COVID-19. Am J Transplant, 20(11):3182-3190.

[35]RECOVERYCollaborative Group, 2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, 397(10285):1637-1645.

[36]RECOVERYCollaborative Group, 2022. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet, 400:359-368.

[37]RECOVERYCollaborative Group, 2023. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, 401(10387):1499-1507.

[38]RichierQ, JachietV, BonnemainsV, et al., 2022. Tocilizumab and COVID-19: timing of administration assessment. Infect Dis Now, 52(1):31-34.

[39]RoncoC, ReisT, Husain-SyedF, 2020. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med, 8(7):738-742.

[40]SaravolatzLD, DepcinskiS, SharmaM, 2023. Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs. Clin Infect Dis, 76(1):165-171.

[41]SinghAK, OksM, HuskG, et al., 2021. Impact of timing of tocilizumab use in hospitalized patients with SARS-CoV-2 infection. Respir Care, 66(12):1805-1814.

[42]SuH, YangM, WanC, et al., 2020. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int, 98(1):219-227.

[43]TalicS, ShahS, WildH, et al., 2021. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis. BMJ, 375:e068302.

[44]TanBWL, TanBWQ, TanALM, et al., 2023. Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: an international multi-centre observational cohort study. eClinicalMedicine, 55:101724.

[45]TatumD, TaghaviS, HoughtonA, et al., 2020. Neutrophil-to-lymphocyte ratio and outcomes in Louisiana COVID-19 patients. Shock, 54(5):652-658.

[46]TuJY, MoXQ, ZhangXD, et al., 2022. Effects of different corticosteroid therapy on severe COVID-19 patients: a meta-analysis of randomized controlled trials. Expert Rev Respir Med, 16(1):79-89.

[47]van GrootveldR, van der BeekMT, JanssenNAF, et al., 2023. Incidence, risk factors and pre-emptive screening for COVID-19 associated pulmonary aspergillosis in an era of immunomodulant therapy. J Crit Care, 76:154272.

[48]WagnerC, GrieselM, MikolajewskaA, et al., 2021. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev, 8(8):CD014963.

[49]WangAX, KoffA, HaoDN, et al., 2022. Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: early experience in four SARS-CoV-2 infected kidney transplant recipients. Am J Transplant, 22(8):2117-2119.

[50]WeissA, HendrickxR, StensgaardE, et al., 2023. Kidney transplant and dialysis patients remain at increased risk for succumbing to COVID-19. Transplantation, 107(5):1136-1138.

[51]WillicombeM, ThomasD, McAdooS, 2020. COVID-19 and calcineurin inhibitors: should they get left out in the storm? J Am Soc Nephrol, 31(6):1145-1146.

[52]ZhangWJ, HanF, WuXF, et al., 2022. COVID-19 in the immunocompromised population: data from renal allograft recipients throughout full cycle of the outbreak in Hubei province, China. Chin Med J, 135(2):228-230.

[53]ZhouZF, KuangH, MaYX, et al., 2021. Application of extracorporeal therapies in critically ill COVID-19 patients. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(9):‍‍701-717.

[54]ZhuL, GongNQ, LiuB, et al., 2020. Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China. Eur Urol, 77(6):748-754.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE